Upstream / Downstream
Explore pathways related to this product.
CST Antibody Performance Guarantee
To Purchase # 11823S
|11823S||300 µl (3 nmol)|
Find answers on our FAQs page.
PTM information and tools available.
SignalSilence® HELLS siRNA II #11823
Western blot analysis of extracts from DLD-1 cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-), SignalSilence® HELLS siRNA I #11822 (+), or SignalSilence® HELLS siRNA II (+), using HELLS Antibody #7998 (upper) or β-Actin (D6A8) Rabbit mAb #8457 (lower). The HELLS Antibody confirms silencing of HELLS expression, while the β-Actin (D6A8) Rabbit mAb is used as a loading control.Learn more about how we get our images
Gallery: SignalSilence® HELLS siRNA II #11823
CST recommends transfection with 100 nM SignalSilence® HELLS siRNA II 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.Storage: SignalSilence® siRNA is supplied in RNAse-free water. Aliquot and store at -20ºC.
SignalSilence® HELLS siRNA II from Cell Signaling Technology (CST) allows the researcher to specifically inhibit HELLS expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
HELLS, or LSH1, is a lymphoid-specific helicase thought to be involved in cellular proliferation and leukemogenesis (1,2). It is believed to be a chromatin remodeler and is required for DNMT1-mediated methylation maintenance and DNMT3A/DNMT3B-mediated de novo methylation. The role of HELLS in methylation maintenance was thought to be largely confined to repetitive DNA sequences, including major and minor satellite sequences, rather than single copy genes (3,4); recent evidence suggests a role in genome-wide cysteine methylation at non-repeat sequences (5). De novo methylation maintenance is associated with silencing of specific genes, some known to be involved in pluripotency and lineage commitment (6,7).
For Research Use Only. Not For Use In Diagnostic Procedures. Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc. SignalSilence® is a trademark of Cell Signaling Technology, Inc.